ATC Group: D10AF Antiinfectives for treatment of acne

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of D10AF in the ATC hierarchy

Level Code Title
1 D Dermatologicals
2 D10 Anti-acne preparations
3 D10A Anti-acne preparations for topical use
4 D10AF Antiinfectives for treatment of acne

Group D10AF contents

Code Title
D10AF01 Clindamycin
D10AF02 Erythromycin
D10AF03 Chloramphenicol
D10AF04 Meclocycline
D10AF05
D10AF06
D10AF07
D10AF51 Clindamycin, combinations
D10AF52 Erythromycin, combinations

Active ingredients in D10AF

Active Ingredient Description
Chloramphenicol

Chloramphenicol is a broad spectrum antibiotic which has activity against many types of Gram-positive and Gram-negative bacteria. It acts by interfering with bacterial protein synthesis. Chloramphenicol is widely distributed in body tissues and fluids and enters the cerebrospinal fluid.

Clindamycin

Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against Gram-positive aerobes and a wide range of anaerobic bacteria. Lincosamides such as clindamycin bind to the 50S subunit of the bacterial ribosome and inhibit the early stages of protein synthesis.

Erythromycin

Erythromycin exerts its antimicrobial action by binding to the 50S ribosomal sub-unit of susceptible microorganisms and suppresses protein synthesis. Erythromycin is bacteriostatic and bactericidal depending on its concentration and the type of organism.

Minocycline

Minocycline is a semi-synthetic derivative of tetracycline. Minocycline inhibits protein synthesis in susceptible bacteria. In common with other tetracyclines it is primarily bacteriostatic and has a similar spectrum of activity to other tetracyclines.

Nadifloxacin
Sulfacetamide

The sulfonamides are bacteriostatic agents and the spectrum of activity is similar for all. Sulfonamides inhibit bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with aminobenzoic acid through competitive inhibition of the enzyme dihydropteroate synthetase.

Related product monographs

Title Information Source Document Type  
AKNEMYCIN PLUS Cutaneous solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CLINDAMYCIN Capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CLINDAMYCIN Solution for Injection or Infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CLINDOXYL Gel Health Products Regulatory Authority (ZA) MPI, Generic
DALACIN C Capsule Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
DALACIN CREAM Vaginal Cream Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
DALACIN T Topical solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ZINDACLIN Gel Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ZINERYT Powder and solvent for solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC